본문으로 건너뛰기
← 뒤로

Generation of a Rabbit Anti-Canine CD19 Monoclonal Antibody From Peripheral Blood and Its Validation in Immunoassays and CAR-T Feasibility.

1/5 보강
Veterinary and comparative oncology 📖 저널 OA 80% 2025: 7/8 OA 2026: 9/12 OA 2025~2026 2026
Retraction 확인
출처

Li H, Lu Q, Huang X, Li M, Zhou Y, Chen M

📝 환자 설명용 한 줄

Lymphoma constitutes 24% of canine neoplastic diseases and 85% of haematopoietic tumours, with B-cell subtypes accounting for 60%-80% of cases.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Li H, Lu Q, et al. (2026). Generation of a Rabbit Anti-Canine CD19 Monoclonal Antibody From Peripheral Blood and Its Validation in Immunoassays and CAR-T Feasibility.. Veterinary and comparative oncology. https://doi.org/10.1111/vco.70061
MLA Li H, et al.. "Generation of a Rabbit Anti-Canine CD19 Monoclonal Antibody From Peripheral Blood and Its Validation in Immunoassays and CAR-T Feasibility.." Veterinary and comparative oncology, 2026.
PMID 41847725 ↗
DOI 10.1111/vco.70061

Abstract

Lymphoma constitutes 24% of canine neoplastic diseases and 85% of haematopoietic tumours, with B-cell subtypes accounting for 60%-80% of cases. As the most prevalent spontaneous tumour in canines, this disease model holds significant translational value for human non-Hodgkin lymphoma research. To address diagnostic limitations in canine B-cell lymphoma, we developed a canine-specific CD19 monoclonal antibody (HAC19.1) with high affinity and established a dual-platform detection system compatible with flow cytometry and immunohistochemistry. Additionally, a novel CD19-targeting chimeric antigen receptor (CAR) gene sequence (HUA-1) was engineered and successfully transduced into Jurkat cells via lentiviral vectors, confirming stable CAR membrane expression. This breakthrough provides critical technical groundwork for advancing autologous CAR-T cell therapy in canines.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반